> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Regulatory Review Period Determined for Uromedica’s Proact
- URL: https://www.fdaweb.com/regulatory-review-period-determined-for-uromedicas-proact/
- Published: 2018-01-12T12:00:00.000Z
- Updated: 2026-09-14T23:13:27.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5140487

*Federal Register* notice: FDA has determined that the regulatory review period for Uromedica’s Proact Adjustable Continence Therapy For Men was 3,892 days. Of this time, 3,179 days occurred during the testing phase and 713 days occurred during the approval phase. The device is indicated for treating adult men who have stress incontinence arising from intrinsic sphincter deficiency of at least 12 months duration following radical prostatectomy or transurethral resection of the prostate and who have failed to respond adequately to conservative therapy. To view the notice, click [here](https://www.gpo.gov/fdsys/pkg/FR-2018-01-12/pdf/2018-00404.pdf?ref=fdaweb.com).